Real-World Study Shows Psilocybin Improves Treatment-Resistant Depression Symptoms

Psilocybin administered to patients with treatment-resistant depression (TRD) in routine clinical practice was associated with clinically meaningful improvements in depressive symptoms.

Results of a small real-world study provide some of the first systematically collected evidence of psilocybin's use in routine clinical practice, including in patients with complex, difficult-to-treat depression who are often excluded from clinical trials.

Although some participants received up to four psilocybin sessions, investigators found no clear signal that additional treatments conferred added benefit.